‘We were attracted to Biopta because they are able to provide sensitive and accurate information from a wide range of different types of tissue, which similar companies cannot do. They can also combine standard screening with valuable information on mechanism, I was impressed with that.’
CEO, UK Biotech
‘Biopta's human tissue services have played a critical part in our compound selection and have added considerable value to our lead compound. At our last round of funding, the investors were reassured by the presence of functional data on living human tissues.’
President & Head of R&D, Canadian Biotech